Januvia (sitagliptin) impairs the immune system.
January 1
Januvia helps treat diabetes by inhibiting the breakdown of incretins...hormones that increase insulin release in response to meals. It does this by blocking dipeptidyl peptidase-4 (DPP-4), an enzyme that inactivates incretins.
Some experts are concerned there may be rare effects associated with other substrates of DPP-4. These may involve immune function including inhibition of T-cell activity.
These concerns are fueled by reports of necrotic skin lesions in monkeys taking another "gliptin" up for approval called Galvus (vildagliptin).
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote